SCHEMBL20738499

SCHEMBL20738499

CC(=O)N1CCc2ccc(CO)cc2CC1

nearest known ligand 0.50

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.50
HRH3 Q9Y5N1 4/20 0.49
FNTA P49354 1/20 0.45
FNTB P49356 1/20 0.45
MCHR1 Q99705 7/20 0.42
F10 P00742 2/20 0.41
PTAFR P25105 1/20 0.41
RORC P51449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18584721 0.85 NAMPT (0.42)
SCHEMBL10205360 0.83 NOTUM (0.46) NOTUMHRH3MCHR1F10PTAFR
SCHEMBL12683270 0.81 DRD2 (0.50) HRH3
SCHEMBL12660102 0.80 NOTUM (0.56) NOTUMHRH3RORC
SCHEMBL1787313 0.80 ESR2 (0.59)
SCHEMBL27914873 0.79 NAMPT (0.49) NOTUM
SCHEMBL16634622 0.79 NAMPT (0.49) NOTUM
SCHEMBL8224502 0.78 NOTUM (0.59) NOTUMHRH3MCHR1F10
SCHEMBL12960968 0.78 NOTUM (0.59) NOTUMHRH3
SCHEMBL9057753 0.78 NOTUM (0.58) NOTUMHRH3MCHR1PTAFRRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOTUM 4102/4885HRH3 719/4885FNTA 3638/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 NOTUM 4102/4885HRH3 719/4885FNTA 3638/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOTUM 4156/4885HRH3 729/4885FNTA 3674/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 NOTUM 4102/4885HRH3 719/4885FNTA 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.